Journal of Nuclear Medicine and Radiation Therapy最新文献

{"title":"A Case Report of False Positive FDG- PET/CT Mediastinal Lymph Node in Oesophageal Adenocarcinoma Revealed to be an Anthracotic and Anthracosilicotic Spindle Cell Pseudotumor (AASCP)","authors":"Mohamad B. Haidar, S. Bannoura, A. Hallal, Ghanem Aa, M. Y. Dergham, Andrew Barakat, Mario Jreige, N. Shabb","doi":"10.4172/2155-9619.1000335","DOIUrl":"https://doi.org/10.4172/2155-9619.1000335","url":null,"abstract":"Anthracotic and anthracosilicotic spindle cell proliferation (AASCP) is a rare reactive proliferative entity of phagocytic histiocytes which can affect hilar and mediastinal lymph nodes. Fluorodeoxyglucose-positron emission tomography (FDG-PET) has been used for the clinical diagnosis and staging of oesophageal adenocarcinoma. We report the first case of AASCP exhibiting false positivity on FDG-PET imaging. A 76-year-old man with distal esophageal adenocarcinoma underwent PET/CT for staging revealing a positive mediastinal lymph node involvement. The patient underwent Endobronchial Ultrasound Fine Needle Aspiration Biopsy (EBUS-FNA) followed by an oesophagectomy with lymph node dissection. The histological diagnosis of the mediastinal lymphadenopathy was AASCP. In mediastinal lymph nodes of esophageal adenocarcinoma, AASCP could be a cause of false-positivity on FDG-PET imaging.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"34 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"127384713","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Parotid Epidermoid Carcinoma: A Case Report","authors":"J. Kambiré, S. Ouédraogo, M. Zida, S. Traoré","doi":"10.4172/2155-9619.1000334","DOIUrl":"https://doi.org/10.4172/2155-9619.1000334","url":null,"abstract":"Introduction: Malignant parotid tumors are rare. They are characterized by their histological diversity dominated by muco-epidermoid tumors and adenocarcinomas; squamous cell carcinomas are much rarer. Result: We report a case of carcinoma not very differentiated from the parotid evolving for 6 years to reach 15 cm of major axis at the time of its diagnosis in a 35-year-old woman. Conclusion: Epidermoid carcinomas, although rare, are not exceptional. Their management is based on total parotidectomy provided that the diagnosis is early. Population education is required for a first-line use of health services in front of any indolor swelling in the parotid region.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"445 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-06-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123053574","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Exceptional Therapeutic Outcome of Metastatic Neuroendocrine Tumor withPeptide Receptor Radionuclide Therapy with Brief Review of Literature","authors":"Manoj Gupta, P. Choudhury, Shivendra Singh, A. Mehta","doi":"10.4172/2155-9619.1000333","DOIUrl":"https://doi.org/10.4172/2155-9619.1000333","url":null,"abstract":"NETs are rare, heterogeneous group of neoplasm presented as chronic oncologic disease. Somatostatin analogue is the standard first line systemic therapy for mainly hormone control. No standard second line systemic treatment is available except everolimus which has no reported complete response. PRRT is an innovative molecular targeted treatment based on theragnostic concept for well differentiated NETs. We presented here a 63-year-old lady with grade 1 NET of rectum with lymphnodal and liver metastasis. She underwent sigmoid colostomy for bowel symptoms and started on sandostatin LAR. After progression, patient was treated with 4 cycles of 7.4GBq of 177Lu-DOTATATE at 10 weeks interval. No hematological and renal toxicity were noticed. Patient showed complete response in liver lesions & lymphnodes and partial response in rectal lesion on 68Ga-DOTANOC PET-CT. After multispecialty clinic board discussion, patient underwent curative surgery for residual rectal lesion and colostomy closer later on. Our case highlights a common presentation of NETs but an uncommon outcome with currently approved drugs. With this potential of disease cure in metastasis, PRRT may also be offered for locally advance disease as an adjuvant treatment for down staging.fv","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"35 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"128347233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Tc-99m MAA Mapping Prior to Y-90 Liver Radioembolization; Factors that mayaffect Pulmonary Shunt Fraction","authors":"F. Behnia, D. Hippe, Mohammad Saad Bermo, S. Elojeimy, H. Vesselle","doi":"10.4172/2155-9619.1000332","DOIUrl":"https://doi.org/10.4172/2155-9619.1000332","url":null,"abstract":"Purpose: To evaluate differences in shunt fraction and possible factors contributing to these differences in patients undergoing Tc-99m macroaggregated albumin (MAA) mapping prior to selective internal radiation therapy (SIRT) with Y-90 microspheres. Materials and methods: Retrospective analysis was performed on data from 130 patients with hepatocellular carcinoma (HCC) or liver metastases, who underwent Y-90 radioembolization over a 6-year period. All patients who received treatment had undergone Tc-99m MAA mapping. Overall 141 Tc-99m MAA injections and 199 Y-90 treatments were performed. Three patients did not qualify for Y-90 treatment following Tc-99m MAA mapping due to high pulmonary shunt fraction. We compared pulmonary shunt fraction between patients with HCC and those with metastatic liver disease and between patients who had mapping of the entire liver, versus selective mapping of the affected segment. Three types of statistical analysis tests were performed: Kolmogorov-Smirnov (KS), Mann- Whitney (MW) and Fligner-Killeen (FK) tests. Results: Although HCC and non-HCC groups had similar distribution of shunt fractions qualitatively, relatively large shunt fractions were slightly more common in HCC group. In diffuse injections, most of the shunt fractions were concentrated between 0 and 5%, but with a long tail to the right. In more selective injections, most were concentrated between 0 and 10%. There was a trend for overall higher median shunt fraction in the diffuse mapping group compared with the selective mapping group, however this was only statistically significant in the HCC patients subset (median shunt of 3.2% in diffuse vs. 6.1% in selective group; p=0.001). Conclusions: Shunt fraction is overall higher in HCC, likely due to underlying cirrhosis as well as intratumoral arteriovenous shunting. Shunt fraction also tends to be higher when the affected liver is selectively injected compared with when the entire liver is being mapped.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"24 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-05-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"123593937","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Utilization of Radioimmunotherapy (RIT) and Hematopoietic Stem CellTransplantation (HSCT) in B-cell Non-HodgkinâÂÂs Lymphoma (NHL): 10 YearExperience of a Single Community Cancer Center","authors":"Nibal Saad, K. Kolizeras, S. Szpunar, A. Al-Katib","doi":"10.4172/2155-9619.1000331","DOIUrl":"https://doi.org/10.4172/2155-9619.1000331","url":null,"abstract":"After Yttrium (Y90) Ibritumomab tiuxetan (Zevalin) and Iodine (131I) tositumomab (Bexxar) were approved by the \u0000 FDA, the improved response of B-cell NHL to this novel RIT makes it a promising alternative to more aggressive \u0000 treatment like HSCT. In this study, we describe the experience of a single community-based cancer with RIT and \u0000 HSCT in patients with B-cell NHL in terms of response, survival and toxicity. Retrospectively, we reviewed 75 \u0000 patients with B cell NHL who were treated with either RIT (N=50) or HSCT (N=25) between 2003 and 2013. Choice \u0000 of treatment modality, i.e. RIT vs. HSCT was based on discretion of treating Oncologist taking into consideration \u0000 patient’s age, performance status, comorbidity and preferences. RIT-treated patients were older. HSCT was more \u0000 likely to be used in aggressive lymphoma and as a consolidation of primary therapy. RIT was used mainly in indolent \u0000 lymphoma and as salvage treatment. Overall response rates were better in HSCT-treated patients (100% vs. 76%). \u0000 Median overall survival was higher in HSCT-treated patients (221 vs. 79.4 months). Similar results were obtained \u0000 when we compared OS in patients younger than 60 years (221 vs. 79.4 months) and in patients with aggressive \u0000 lymphoma (221 vs. 59.7 months). PFS was not met in HSCT, while it was 16.2 months in RIT. Myelodysplastic \u0000 syndrome (MDS) occurred in both groups (12% HSCT vs. 2% RIT). Thrombocytopenia was more prevalent with RIT. \u0000 All other toxicities were significantly more common with HSCT. This study shows that, in clinical practice, younger \u0000 patients with aggressive B-cell NHL and without significant comorbidity are more likely to be offered HSCT. On the \u0000 other hand, RIT was offered to older patients with indolent histology. Our results show that RIT is a reasonable \u0000 alternative salvage treatment modality for B-cell NHL patients who are not candidates for HSCT.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"555 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"133350370","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The results of a TLD Therapy Dosimetry Quality Assurance Program for Dong Nai General Hospital, Vietnam (Period 2013-2017)","authors":"D. Tai, Truong Thiet Dung","doi":"10.4172/2155-9619.1000330","DOIUrl":"https://doi.org/10.4172/2155-9619.1000330","url":null,"abstract":"The objective of this study is to perform a thermo luminescent dosimetry (TLD) postal dose audit provided the \u0000 International Atomic Energy Agency (IAEA) for a linear accelerator in Dong Nai General Hospital. The TLD were \u0000 irradiated with an absorbed dose to water of 2 Gy for 6 MV and 15 MV photon beams generated by a linear \u0000 accelerator (LINAC) (Siemens Medical Solutions, Concord, CA). The percentage deviation relative to IAEA \u0000 measured dose was 0.4% and 3.4% for 6 MV and 16 MV, respectively. Agreement within ± 5% between the users \u0000 stated dose and the IAEA measured dose is considered satisfactory. The results showed that all photon beams are \u0000 within the IAEA’s acceptance limit of ± 5%. As a conclusion, the beam output of Siemens Primus is accuracy in \u0000 delivery of absorbed dose within ± 5%.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"18 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"126095591","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association of PET Scan Parameters of Pulmonary Masses and Reticuloendothelial System with Hematologic Parameters","authors":"H. Komek, S. Altindağ, C. Can","doi":"10.4172/2155-9619.1000327","DOIUrl":"https://doi.org/10.4172/2155-9619.1000327","url":null,"abstract":"Objectives: The most active organs of the reticuloendothelial system (RES) are the liver, spleen and bone marrow, having immune mechanisms against malignancy including neutrophils and platelets. RES may be imaged by different modalities, like PET scan. Neutrophil lymphocyte ratio (NLR) and platelet lymphocyte ratio (PLR) have gained importance as proinflammatory markers in cancer, e.g. lung cancer. The aim of this study was to investigate the relationship between PET parameters of pulmonary mass or RES, and hematological parameters, and to evaluate the role of these factors in differentiating the pathological character of the mass. Methods: A retrospective analysis of the data of 131 patients, retrieved from the department archives, with pulmonary mass limited to mediastinum was made. Patients were grouped according to pathological results: benign mass (n=46), squamous cell carcinoma (n=38), and non-squamous cancer of lung (n=47). All patients underwent PET/CT scanning and images were analyzed retrospectively. Maximum and mean SUV were calculated from primary lesions and RES. NLR and PLR were calculated from CBC. Results: SUVmax and SUVmean of RES organs were similar for both groups with benign and malignant pulmonary masses, and among the subgroups. SUVmax ratios of pulmonary mass were significantly different between the groups (the highest value in the squamous cell carcinoma and the lowest in the benign groups). No significant difference was determined between the subgroups for NLR and PLR. NLR was significantly correlated with SUVmax ratios of spleen and the mass, and SUVmean ratios of spleen and bone marrow. PLR was significantly correlated with SUVmax ratios of spleen, bone marrow, the mass and SUVmean ratios of spleen, bone marrow. Conclusion: SUV of RES and primary mass were correlated with NLR and PLR, indicators of systemic inflammation. The associations between NLR and PLR, and SUV should be clearly defined by further investigations.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"10 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"130756381","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term Results of a Pilot Study Comparing FLT-PET and FDG-PET in the Evaluation of Response to Treatment in Advanced Head and Neck and Esophageal Malignancies","authors":"R. Youland, V. Lowe, R. Foote, D. Pafundi, S. Okuno, RobertI Miller, S. Alberts, D. Brinkmann, J. Sarkaria","doi":"10.4172/2155-9619.1000328","DOIUrl":"https://doi.org/10.4172/2155-9619.1000328","url":null,"abstract":"Objective: We prospectively compared FDG-PET and FLT-PET in assessing patient responses to induction cetuximab and/or chemoradiotherapy (CRT) for advanced head and neck squamous cell carcinoma (HNSCC) and esophageal cancer (EC). \u0000Methods: Sixteen patients were enrolled, 9 with HNSCC and 7 with EC. FDG-PET and FLT-PET scans were performed at baseline and two weeks into chemoradiotherapy (CRT) for patients with EC. Patients with HNSCC received two weeks of induction chemotherapy along with post-induction PET scans prior to starting CRT in addition to the baseline and intra-chemoradiotherapy PET scans. Changes in SUVmax and total lesion glycolysis/ proliferation (TLG/TLP) were compared with baseline. \u0000Results: Median follow-up for living patients was 6.0 years. Median overall survival (OS) was 3.3 years and progression-free survival (PFS) was 2.5 years. Patients with HNSCC had higher baseline SUVmax, TLG and TLP than those with EC. Changes in SUVmax, TLG and TLP after induction chemotherapy or during CRT did not correlate with PFS or OS. Those with >40% decline in SUVmax on FDG-PET six weeks after completing CRT had better PFS (p 70% decrease in posttreatment TLG correlated with better PFS (p=0.03) and OS (p=0.04). \u0000Conclusions: Functional imaging performed early during chemoradiotherapy for advanced HNSCC and EC is feasible. Changes on post-induction and intra-CRT FLT and FDG PET did not correlate with PFS or OS. However, better PFS and OS were seen in patients with >40% decline in SUVmax and >70% decrease in TLG on FDG-PET performed six weeks after completing CRT. Further research is needed to determine the prognostic impact of PET performed during chemotherapy and radiotherapy.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"36 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"132744383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of Incidental Radiation Dose to Axilla and Internal Mammary Nodal Area by Conventional, 3DCRT, and IMRT Technique in Carcinoma of Breast","authors":"H. Govardhan, N. Thimmaiah, Khaleel Ia, S. Pradhan, R. Jain","doi":"10.4172/2155-9619.1000325","DOIUrl":"https://doi.org/10.4172/2155-9619.1000325","url":null,"abstract":"Purpose: To quantify the incidental radiation dose delivered to axilla and internal mammary nodal (IMN) area by Conventional Tangential Radiation Therapy (CRT), 3 Dimensional Conformal Radiation Therapy (3DCRT) and Intensity Modulated Radiation Therapy (IMRT). \u0000Methods and Materials: We prospectively evaluated incidental radiation to axilla in twenty cases of breast cancer treated with adjuvant radiation therapy. Three plans were generated for each case, comprising CRT, 3DCRT and IMRT tangents. Radiation doses to axillary levels I, II, III, and IMN areas were evaluated for mean dose, V95, V80 and V50. Comparisons were made using ANOVA. \u0000Results: The mean volume and range of the axillary level I, II, III, and IMN were 61.1 cc and 142-57 cc; 42.6 cc and 61-21cc; 19.5 cc and 34-15 cc; 13.2 cc and 21-9 cc respectively. The mean dose to axilla by 3 techniques (by IMRT, 3DCRT and CRT) to Level I, II, III, and IMN were 75%, 53%, 38%, and 61% vs. 81%, 64%, 44% and 77% vs. 92%, 86%, 53% and 92% respectively (p<0.05). The V95 values (volume receiving 95% of dose) for the three techniques were 43%, 39%, 17% and 49% by IMRT: 40%, 45%, 21% and 59% by 3DCRT; 72%, 61%, 24% and 65% by CRT (IMRT vs. 3DCRT for level II axilla, IMRT vs. CRT and 3DCRT vs. CRT-p<0.05) The V80 were 49%, 53%, 29%, and 57% by IMRT; 55%, 47%, 34% and 68% by 3DCRT; 85%, 77%, 44% and 69% by CT (IMRT vs. 3DCRT for level III axilla and IMN, IMRT vs. CRT and 3DCRT vs. CRT -p<0.05). The V50 values were 75%, 65%, 41% and 66% by IMRT; 82%, 53%, 57% and 84% by 3DCRT; 94%, 89%, 42% and 90% by CRT (IMRT vs. 3DCRT, IMRT vs. CRT, and 3DCRT vs. CRP–p<0.05). \u0000Conclusion: Axillary and internal mammary nodal areas receive substantial amount of incidental radiation doses with all the three techniques; however, conformal techniques (IMRT, 3DCRT) deliver significantly lesser incidental radiation to lower axilla than CRT technique.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"12 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"125287820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of TomoTherapy and RapidArc in Hippocampus Sparing Brain Radiotherapy in Pediatrics","authors":"M. Nazmy, A. Mousa, Ghadeer Nazer, B. Moftah, Y. Khafaga","doi":"10.4172/2155-9619.1000326","DOIUrl":"https://doi.org/10.4172/2155-9619.1000326","url":null,"abstract":"Background and Objectives: Both TomoTherapy and RapidArc have been examined in hippocampus sparing whole brain irradiation in adults. We aim to compare both techniques in pediatrics with relatively smaller brain volume. Patients and Methods: The hippocampus, the whole brain and the eyes were manually contoured in 3 pediatric patients. TomoTherapy plan was created aiming at adequate brain coverage and as low as possible hippocampus dose, RapidArc was challenged to achieve similar or better plan results. The prescription dose was 36 Gy in 20 treatment fractions to the whole brain. Results: TomoTherapy was able to achieve a mean hippocampus dose of 13.6 Gy with brain homogeneity index [HI] of 0.14 Using RapidArc [single arc], the same hippocampus dose was not achievable without compromising the brain HI significantly. By using 2 arcs, similar results to the TomoTherapy plan were achieved. The treatment time for TomoTherapy was 3.5 minutes while it was 1.2 minutes for single arc and 2.4 minutes for two arcs. Conclusions: TomoTherapy can achieve better target coverage with lower doses to the hippocampus compared to single arc RapidArc technique, while using 2 arcs RapidArc can achieve similar results with shorter treatment time.","PeriodicalId":302578,"journal":{"name":"Journal of Nuclear Medicine and Radiation Therapy","volume":"5 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2017-01-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116833740","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}